Augmentin Patent Case Ruling

GlaxoSmithKline PLC
23 November 2003

               US Court of Appeals Rules in Augmentin Patent Case


LONDON, November 21, 2003 -- GlaxoSmithKline (GSK) today announced that the US
Court of Appeals for the Federal Circuit in Washington, DC has ruled in favour
of Geneva Pharmaceuticals, Teva Pharmaceuticals and Ranbaxy, and upheld lower
court rulings that invalidated GSK's US patents for its antibiotic Augmentin.

GSK continues to be committed to its newer Augmentin antibiotic medicines --
Augmentin ES and XR-- which now represent nearly 35% of the total number of
prescriptions being written for branded and generic Augmentin.


S M Bicknell

Company Secretary

21st November 2003


About GSK:

GlaxoSmithKline, one of the world's leading research-based pharmaceutical and
healthcare companies, is committed to improving the quality of human life by
enabling people to do more, feel better and live longer. For more information,
please visit the company's web site at www.gsk.com.

Inquiries:

US Media Inquiries:                Nancy Pekarek               [phone]
                                   Mary Anne Rhyne             [phone]
                                   Patricia Seif               [phone]

UK Media Inquiries:                Martin Sutton               [phone]
                                   Chris Hunter-Ward           [phone]
                                   David Mawdsley              [phone]

European Analyst/
Investor enquiries:                Duncan Learmouth            [phone]
                                   Anita Kidgell               [phone]
                                   Philip Thomson              [phone]

US Analyst/ Investor enquiries:    Frank Murdolo               [phone]
                                   Tom Curry                   [phone]




                      This information is provided by RNS
            The company news service from the London Stock Exchange